Last reviewed · How we verify

Biologische Heilmittel Heel GmbH — Portfolio Competitive Intelligence Brief

Biologische Heilmittel Heel GmbH pipeline: 0 marketed, 0 filed, 3 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Saline inj Saline inj phase 3 Fluid, Electrolyte, and Acid-Base Balance
Traumeel S inj Traumeel S inj phase 3 Homeopathic remedy Pain management, Inflammation
Traumeel® / Zeel® Injectable Solution Traumeel® / Zeel® Injectable Solution phase 3 Homeopathic combination remedy Rheumatology / Musculoskeletal / Pain Management

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Charite University, Berlin, Germany · 1 shared drug class
  2. Hevert-Arzneimittel GmbH & Co. KG · 1 shared drug class
  3. University Hospital, Grenoble · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Biologische Heilmittel Heel GmbH:

Cite this brief

Drug Landscape (2026). Biologische Heilmittel Heel GmbH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/biologische-heilmittel-heel-gmbh. Accessed 2026-05-17.

Related